The short answer
Do not self-start L-5-HTP with fluoxetine. Official supplement guidance advises against antidepressant co-use, despite a small supervised 5-hydroxytryptophan augmentation trial.
What this answer covers
Oral L-5-HTP requested; the trial’s reported 5-hydroxytryptophan product has incomplete exact isomer and preparation documentation.
- Supplement or preparation
- L-5-HTP
- Medication ingredient
- fluoxetine
The supplement warning remains relevant
Health Canada advises not to use L-5-HTP with antidepressants. Any proposed augmentation belongs in a prescriber-led decision.
A supervised trial found possible benefit
A twelve-week OCD trial combined fluoxetine with 5-hydroxytryptophan and found better symptom outcomes than placebo augmentation. It does not establish benefit for every diagnosis.
Benefit did not mean absence of adverse effects
Abdominal pain and constipation were more common in the precursor arm. No adverse-event withdrawals were reported, but the small study and incomplete exact product characterization do not establish routine supplement safety.
Recognize concerning symptoms
Seek urgent medical care for a combination of agitation or confusion, fever or heavy sweating, tremor, muscle rigidity or repeated twitching. These can be signs of serotonin syndrome; a single nonspecific symptom does not establish the diagnosis.
Evidence and practical considerations
Side effects & toxicity
Conditional avoidance of unsupervised use, retaining human augmentation evidence rather than claiming universal observed toxicity.
- Exact scope
- Oral L-5-HTP requested; the trial’s reported 5-hydroxytryptophan product has incomplete exact isomer and preparation documentation. with Exact oral fluoxetine hydrochloride capsules. RxNorm IN 4493/PIN 227224 hydrochloride capsules. Active norfluoxetine and prolonged elimination matter. Not the combined olanzapine product.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- Sixty randomized and fifty-two analyzed; exact L-product bridge limited, uncommon serotonin toxicity and long-term safety not established.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral fluoxetine.
Exact label names tryptophan and St John’s wort in serotonin warnings, warns about bleeding and mania, and describes long elimination of fluoxetine and norfluoxetine.
How this applies: RxNorm IN 4493/PIN 227224 hydrochloride capsules. Active norfluoxetine and prolonged elimination matter. Not the combined olanzapine product.
No universal supplement interval, event rate or preparation equivalence established. Original label distinguishes warnings from measured pair-specific results.
Source 2: official product guidance
webprod.hc-sc.gc.ca · Source check Sep 10, 2026
Population: Adults considering oral L-5-HTP.
Advises not to use with antidepressants; gives serotonergic product precautions and drowsiness caution.
How this applies: The requested medicine is an antidepressant; this is a product-label precaution, not exact-pair clinical proof.
Does not quantify risk with each specific antidepressant or establish a safe supplement dose.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Sixty adults with moderate to severe OCD randomized; fifty-two analyzed at twelve weeks.
OCD outcomes favored augmentation; abdominal pain and constipation were more common, other adverse effects generally similar, and no adverse-event withdrawals were reported.
How this applies: Only the named drug, preparation, route and measured endpoints apply.
Paper calls product 5-hydroxytryptophan without adequate exact L-isomer/product assay documentation. Small complete-case analysis; not proof against rare serotonin toxicity or a general supplement dose recommendation.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. | |
| Research summary published |
Article revision: 9d3c7d6a653f0cc0
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.